Evidence supporting the use of: L-citrulline
For the health condition: Congestive Heart Failure

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

L-citrulline is a non-essential amino acid involved in the urea cycle and is a precursor to L-arginine, which is subsequently converted to nitric oxide (NO), an important vasodilator. Several small clinical studies and experimental models have explored the use of L-citrulline in the context of cardiovascular health, including congestive heart failure (CHF). The rationale is that by increasing nitric oxide production, L-citrulline may promote vasodilation, reduce vascular resistance, and improve hemodynamics, which are often compromised in CHF patients.

Some trials have shown that L-citrulline supplementation can increase plasma arginine levels more effectively than arginine itself and may improve endothelial function. A few small-scale studies have reported improvements in exercise capacity and cardiac function in heart failure patients, potentially due to enhanced vasodilation and improved oxygen delivery. However, most studies are limited by small sample sizes, short durations, and varying dosages.

Systematic reviews and meta-analyses have generally concluded that while L-citrulline shows promise for improving vascular function, the evidence specifically supporting its use in congestive heart failure is limited and not yet robust. Larger, well-designed clinical trials are needed to confirm these preliminary findings and establish clear therapeutic guidelines. Thus, the use of L-citrulline in CHF is scientifically plausible and supported by some early clinical evidence, but overall, the current evidence base is rated as low to moderate (2/5).

More about L-citrulline
More about Congestive Heart Failure